# Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients

Study · id `cardio:ct-nct01610141` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01610141](<https://clinicaltrials.gov/study/NCT01610141>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01610141

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems; Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

## Technical summary

Registry record NCT01610141. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2014-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT01610141, source copy `cardio:ctgov-nct01610141-2013-10-09`, retrieved 2026-10-26)
- Start date: 2012-06 (registry gives no type) (ClinicalTrials.gov record NCT01610141, source copy `cardio:ctgov-nct01610141-2013-10-09`, retrieved 2026-10-26)
- Primary completion: 2014-06 (anticipated) (ClinicalTrials.gov record NCT01610141, source copy `cardio:ctgov-nct01610141-2013-10-09`, retrieved 2026-10-26)
- Completion: 2015-06 (anticipated) (ClinicalTrials.gov record NCT01610141, source copy `cardio:ctgov-nct01610141-2013-10-09`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01610141, source copy `cardio:ctgov-nct01610141-2013-10-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01610141-2013-10-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients
- Condition: Atrial Fibrillation
- Condition: Deep Vein Thrombosis
- Condition: Pulmonary Embolism
- Condition: Heart Valve Disease
- Intervention (Other): Genotype-guided warfarin dosing
- Intervention (Other): Non-genotype guided warfarin dosing
- Lead sponsor: Chinese PLA General Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: Chinese PLA General Hospital (`cardio:org-chinese-pla-general-hospital`)

## Provenance

Content hash: 2a212f6a87ae35f977192343c2b17924838ddaa3e0122619818fc0c817b18431
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
